Alyeska Investment Group L.P. Boosts Stock Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT)

Alyeska Investment Group L.P. boosted its stake in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 175.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,707,497 shares of the company's stock after purchasing an additional 1,725,824 shares during the quarter. Alyeska Investment Group L.P. owned approximately 2.33% of Applied Therapeutics worth $2,318,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Barclays PLC lifted its stake in Applied Therapeutics by 186.1% during the third quarter. Barclays PLC now owns 200,012 shares of the company's stock worth $1,702,000 after purchasing an additional 130,102 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in shares of Applied Therapeutics by 18.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 313,355 shares of the company's stock valued at $268,000 after acquiring an additional 47,983 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Applied Therapeutics by 169.0% in the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company's stock worth $35,000 after buying an additional 25,601 shares during the period. Private Advisor Group LLC bought a new stake in Applied Therapeutics in the fourth quarter valued at $35,000. Finally, Swiss National Bank purchased a new stake in Applied Therapeutics in the fourth quarter worth $126,000. Hedge funds and other institutional investors own 98.31% of the company's stock.

Applied Therapeutics Stock Performance

Shares of Applied Therapeutics stock traded up $0.03 during trading on Monday, hitting $0.43. The company's stock had a trading volume of 764,863 shares, compared to its average volume of 3,101,116. The company has a fifty day simple moving average of $0.44 and a two-hundred day simple moving average of $2.15. Applied Therapeutics, Inc. has a 52 week low of $0.30 and a 52 week high of $10.62. The company has a market capitalization of $61.16 million, a PE ratio of -0.27 and a beta of 2.00.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last posted its quarterly earnings data on Monday, April 14th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.06). The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.61 million. As a group, analysts predict that Applied Therapeutics, Inc. will post -0.65 EPS for the current year.

Applied Therapeutics Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.